What type of study is this?

This is a In Vitro Study study.

December 8, 2025BloodOpen Access

Combinatorial targeting of metabolic vulnerabilities in t-cell leukemia through NAMPT inhibition

View Full Paper

Ask AI

Bookmark

Authors

Combination treatment improves tumor progression and overcomes drug resistance in T-ALL, suggesting NAMPT’s role in therapy.

NAMPT inhibition enhances methotrexate sensitivity in T-ALL cells, leading to reduced tumor progression.
T-ALL xenograft models showed prolonged survival with combined NAMPT inhibitors and methotrexate treatment.
The approach integrates metabolomics, transcriptomics, and proteomics to characterize metabolic vulnerabilities.
Findings indicate the potential significance of targeting NAMPT for overcoming resistance in high-risk T-ALL cases.

Guerrero et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Combination treatment improves tumor progression and overcomes drug resistance in T-ALL, suggesting NAMPT’s role in therapy.

NAMPT inhibition enhances methotrexate sensitivity in T-ALL cells, leading to reduced tumor progression.
T-ALL xenograft models showed prolonged survival with combined NAMPT inhibitors and methotrexate treatment.
The approach integrates metabolomics, transcriptomics, and proteomics to characterize metabolic vulnerabilities.
Findings indicate the potential significance of targeting NAMPT for overcoming resistance in high-risk T-ALL cases.

Guerrero et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark